Abstract 4050: Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome
Caroline A. Nebhan(VA Tennessee Valley Healthcare System), Justin M. Balko(Vanderbilt University Medical Center), Paula I. González-Ericsson(Breast Cancer Research Foundation), Henry Gómez(National Cancer Center), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Ju Young Kim(Navidea Biopharmaceuticals (United States)), Roberto Salgado(Institut Jules Bordet)
Cited by 0
Related Papers
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684